Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More
Three dividend stocks stand out in July, offering reliable income, attractive yields, and strong fundamentals to help investors navigate market volatility
Investors monitor shifting market dynamics and consumer behavior post-pandemic, with Sarat Sethi sticking with Johnson & Johnson amid a positive earnings report. Stephen Weiss picks iShares Bitcoin Trust ETF and Joseph Terranova chooses Intercontinental Exchange, with Piper Sandler raising price target for ICE. Johnson & Johnson's FY2025 earnings guidance rose, while iShares Bitcoin Trust ETF and Intercontinental Exchange shares saw varied movement.
Analysts highlighted momentum in oncology and MedTech, with Wells Fargo calling the second-half growth acceleration “achievable” and Morgan Stanley noting visibility risks from drug pricing and tariff policy.
Johnson & Johnson is back in rally mode after years of post-pandemic normalization and the impact of repositioning, set up to sustain higher prices for years.
Volatility surged across interest rate-sensitive assets Wednesday after reports circulated that President Donald Trump may be preparing to remove Federal Reserve Chair Jerome Powell from his post. The rumors sparked fears over the Fed's independ
Let's delve into the developments on the US markets in the middle of the day on Wednesday. Below, you'll find the top gainers and losers within the S&P500 index during today's session.
Multinational healthcare company Johnson & Johnson (NYSE:JNJ) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 5.8% year on year to $23.74 billion. The company’s full-year revenue guidance of $93.3 billion at the midpoint came in 2.1% above analysts’ estimates. Its non-GAAP profit of $2.77 per share was 3.2% above analysts’ consensus estimates.
